Singapore: Genetic Technologies appointed Mr Mark Ostrowski as senior vice president sales and marketing for molecular diagnostics. In this role, Mr Ostrowski will be responsible for managing the US sales effort for BREVAGen, which is the company's cornerstone commercial product.

Mr Mark Ostrowski brings over 20 years of sales and marketing experience in molecular diagnostics having served in senior managerial positions at companies focused on women's health and oncology, including as director, sales operations, Myriad Genetics, and as director, managed care services, DIANON Systems.

During his tenure at Myriad, he managed a sales force of over 200 representatives, demonstrating an average annual revenue growth of over 50 percent and generating new strategic divisions and best practice policies.

Dr Paul MacLeman, CEO, Genetic Technologies, said that, "On behalf of the management team and board, I am delighted to welcome Mark to Genetic Technologies. This is an important period for BREVAGen, as the product transitions from its initial pilot commercial phase to a true national program. Mark's deep knowledge of the diagnostic space and sales managerial leadership will play an integral role in facilitating growth for our flagship product."

Mr Ostrowski said that, "I'm excited to join Genetic Technologies and to spearhead BREVAGen's commercialization efforts. I am looking forward to applying my experience in oncology and women's health diagnostics to BREVAGen, which I feel has the potential to be a keystone product in the evolution of health."